SCHEMBL19981496

SCHEMBL19981496

CCOC(=O)/C=C/C(=O)Nc1nc(CC)c(-c2ccccc2)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.50
MAPT P10636 5/20 0.50
HTT P42858 3/20 0.50
MDM2 Q00987 1/20 0.50
ALDH1A1 P00352 7/20 0.49
THRB P10828 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
HSD17B10 Q99714 1/20 0.49
NPSR1 Q6W5P4 5/20 0.48
RAB9A P51151 2/20 0.48
GSTO1 P78417 2/20 0.48
HPGD P15428 2/20 0.48
AURKA O14965 1/20 0.47
ADORA3 P0DMS8 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ADORA2B P29275 1/20 0.45
KDM4E B2RXH2 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19981509 0.89 ALDH1A1 (0.55) LMNAMAPTHTTMDM2ALDH1A1
SCHEMBL19974431 0.87 ALDH1A1 (0.47) LMNAMAPTHTTALDH1A1THRB
SCHEMBL19974430 0.87 ALDH1A1 (0.47) LMNAMAPTHTTALDH1A1THRB
SCHEMBL23647317 0.87 LMNA (0.50) LMNAMAPTHTTMDM2ALDH1A1
SCHEMBL19981400 0.85 GAA (0.53) LMNAMAPTHTTMDM2ALDH1A1
SCHEMBL19981501 0.85 LMNA (0.48) LMNAMAPTHTTMDM2ALDH1A1
SCHEMBL23657175 0.82 ALDH1A1 (0.42) LMNAMAPTHTTALDH1A1THRB
SCHEMBL19981420 0.77 PARP1 (0.64) LMNAMAPTHTTALDH1A1RAB9A
SCHEMBL19272762 0.77 GSTO1 (0.60) LMNAMAPTHTTMDM2ALDH1A1
SCHEMBL19981570 0.77 NPC1 (0.69) LMNAMAPTHTTMDM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3512602-B1 INHIBITORS OF HEAT SHOCK FACTORS (HSF) AND USES THEREOF HSF PHARMACEUTICALS (CH) 2024-03-27 EP disclosed
US-11597708-B2 Inhibitors of heat shock factors and uses thereof HSF PHARMACEUTICALS SA (CH) 2023-03-07 US disclosed
US-11597708-B2 Inhibitors of heat shock factors and uses thereof HSF PHARMACEUTICALS SA (CH) 2023-03-07 US disclosed
US-20210221778-A1 Inhibitors of heat shock factors and uses thereof HSF PHARMACEUTICALS SA (CH) 2021-07-22 US disclosed
US-20210221778-A1 Inhibitors of heat shock factors and uses thereof HSF PHARMACEUTICALS SA (CH) 2021-07-22 US disclosed
WO-2018050656-A2 INHIBITORS OF HEAT SHOCK FACTORS AND USES THEREOF HSF PHARMACEUTICALS (CH) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11597708-B2 Inhibitors of heat shock factors and uses thereof HSF1, HSP90AB2P, HSP90AB1 LMNA 3549/4885MAPT 2930/4885HTT 1981/4885
US-20210221778-A1 Inhibitors of heat shock factors and uses thereof HSF1, HSP90AB2P, HSP90AB1 LMNA 3549/4885MAPT 2930/4885HTT 1981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.